Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
<h4>Background</h4>We systematically analyzed multiple myeloma (MM) cell lines and patient bone marrow cells for their engraftment capacity in immunodeficient mice and validated the response of the resulting xenografts to antimyeloma agents.<h4>Design and methods</h4>Using fl...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/084d0622fa22403885cc394eda0e439b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:084d0622fa22403885cc394eda0e439b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:084d0622fa22403885cc394eda0e439b2021-11-18T08:48:02ZIntratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.1932-620310.1371/journal.pone.0079939https://doaj.org/article/084d0622fa22403885cc394eda0e439b2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24223204/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>We systematically analyzed multiple myeloma (MM) cell lines and patient bone marrow cells for their engraftment capacity in immunodeficient mice and validated the response of the resulting xenografts to antimyeloma agents.<h4>Design and methods</h4>Using flow cytometry and near infrared fluorescence in-vivo-imaging, growth kinetics of MM cell lines L363 and RPMI8226 and patient bone marrow cells were investigated with use of a murine subcutaneous bone implant, intratibial and intravenous approach in NOD/SCID, NOD/SCID treated with CD122 antibody and NOD/SCID IL-2Rγ(null) mice (NSG).<h4>Results</h4>Myeloma growth was significantly increased in the absence of natural killer cell activity (NSG or αCD122-treated NOD/SCID). Comparison of NSG and αCD122-treated NOD/SCID revealed enhanced growth kinetics in the former, especially with respect to metastatic tumor sites which were exclusively observed therein. In NSG, MM cells were more tumorigenic when injected intratibially than intravenously. In NOD/SCID in contrast, the use of juvenile long bone implants was superior to intratibial or intravenous cancer cell injection. Using the intratibial NSG model, mice developed typical disease symptoms exclusively when implanted with human MM cell lines or patient-derived bone marrow cells, but not with healthy bone marrow cells nor in mock-injected animals. Bortezomib and dexamethasone delayed myeloma progression in L363- as well as patient-derived MM cell bearing NSG. Antitumor activity could be quantified via flow cytometry and in vivo imaging analyses.<h4>Conclusions</h4>Our results suggest that the intratibial NSG MM model mimics the clinical situation of the disseminated disease and serves as a valuable tool in the development of novel anticancer strategies.Julia SchuelerDagmar WiderKerstin KlingnerGabrielle M SiegersAnnette M MayRalph WäschHeinz-Herbert FiebigMonika EngelhardtPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e79939 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Julia Schueler Dagmar Wider Kerstin Klingner Gabrielle M Siegers Annette M May Ralph Wäsch Heinz-Herbert Fiebig Monika Engelhardt Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| description |
<h4>Background</h4>We systematically analyzed multiple myeloma (MM) cell lines and patient bone marrow cells for their engraftment capacity in immunodeficient mice and validated the response of the resulting xenografts to antimyeloma agents.<h4>Design and methods</h4>Using flow cytometry and near infrared fluorescence in-vivo-imaging, growth kinetics of MM cell lines L363 and RPMI8226 and patient bone marrow cells were investigated with use of a murine subcutaneous bone implant, intratibial and intravenous approach in NOD/SCID, NOD/SCID treated with CD122 antibody and NOD/SCID IL-2Rγ(null) mice (NSG).<h4>Results</h4>Myeloma growth was significantly increased in the absence of natural killer cell activity (NSG or αCD122-treated NOD/SCID). Comparison of NSG and αCD122-treated NOD/SCID revealed enhanced growth kinetics in the former, especially with respect to metastatic tumor sites which were exclusively observed therein. In NSG, MM cells were more tumorigenic when injected intratibially than intravenously. In NOD/SCID in contrast, the use of juvenile long bone implants was superior to intratibial or intravenous cancer cell injection. Using the intratibial NSG model, mice developed typical disease symptoms exclusively when implanted with human MM cell lines or patient-derived bone marrow cells, but not with healthy bone marrow cells nor in mock-injected animals. Bortezomib and dexamethasone delayed myeloma progression in L363- as well as patient-derived MM cell bearing NSG. Antitumor activity could be quantified via flow cytometry and in vivo imaging analyses.<h4>Conclusions</h4>Our results suggest that the intratibial NSG MM model mimics the clinical situation of the disseminated disease and serves as a valuable tool in the development of novel anticancer strategies. |
| format |
article |
| author |
Julia Schueler Dagmar Wider Kerstin Klingner Gabrielle M Siegers Annette M May Ralph Wäsch Heinz-Herbert Fiebig Monika Engelhardt |
| author_facet |
Julia Schueler Dagmar Wider Kerstin Klingner Gabrielle M Siegers Annette M May Ralph Wäsch Heinz-Herbert Fiebig Monika Engelhardt |
| author_sort |
Julia Schueler |
| title |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| title_short |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| title_full |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| title_fullStr |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| title_full_unstemmed |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| title_sort |
intratibial injection of human multiple myeloma cells in nod/scid il-2rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/084d0622fa22403885cc394eda0e439b |
| work_keys_str_mv |
AT juliaschueler intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT dagmarwider intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT kerstinklingner intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT gabriellemsiegers intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT annettemmay intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT ralphwasch intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT heinzherbertfiebig intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies AT monikaengelhardt intratibialinjectionofhumanmultiplemyelomacellsinnodscidil2rgnullmicemimicshumanmyelomaandservesasavaluabletoolforthedevelopmentofanticancerstrategies |
| _version_ |
1718421244603269120 |